BSH are sharing this message from the Medicines and Healthcare products Regulatory Agency:
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 Medicines Recall of a specific batch of Mercaptopurine 50mg tablets as a precautionary measure, due to microbial contamination following a small number of complaints of discoloured tablets within the packs, identified when the packs have been opened by healthcare professionals.
Mercaptopurine is a medication used for the treatment of acute leukaemia in adults, adolescents and children. It can also be used to treat ulcerative colitis and Crohn’s disease, although use for these conditions is unlicensed.
Healthcare professionals are asked to quarantine and return the affected batch to their supplier as a precautionary measure.
Patients or carers should check to see if they have received tablets from the listed batch of Mercaptopurine 50 mg tablets (Batch P0010384). The batch number can be found on the label of the medicine bottle.
The tablets should be a ‘pale yellow colour and are marked with ‘PT / 50’, as per the Patient Information Leaflet (PIL). If patients have tablets that are discoloured in any way, from the affected batch they should contact their relevant healthcare professional responsible for their treatment, e.g. specialist or prescriber. For further information, please refer to the recall.